原发性肝癌靶向药物治疗试验与临床研究进展

Progress in basic and clinical research of targeted drugs for primary hepatocellular carcinoma

肝癌是一种高发的消化系统恶性肿瘤,传统的治疗方法对于中晚期肝癌疗效不佳,索拉非尼是第一个用于肝癌治疗的分子靶向药物,靶向药物的出现为中晚期肝癌患者提供了新的选择.近年来,特别是免疫治疗的加入,已发现许多新型靶向药物可明显改善中晚期肝癌患者的预后,因此靶向药物成为了研究热点.本文就近年来肝癌靶向药物治疗试验及临床研究进展做一综述.

Hepatocellular carcinoma is one of the most common malignancies of the digestive system. Traditional treatment is not effective for advanced hepatocellular carcinoma. Sorafenib is the first molecule-targeted drug for hepatocellular carcinoma treatment. The emergence of molecule-targeted drugs provided a new choice for patients with advanced hepatocellular carcinoma. In recent years, thanks to the development of immunotherapy, many new molecule-targeted drugs have been found to significantly improve the prognosis of patients with hepatocellular carcinoma. Therefore, targeted drugs have become a research hotspot. This article reviews the progress in basic and clinical research of molecule-targeted drugs for hepatocellular carcinoma.